Literature DB >> 2835544

A low molecular weight heparin in hemodialysis.

N Maurin1, H Kierdorf.   

Abstract

The purpose of our study was to check whether the dosage recommended for the low molecular weight heparin tested here, i.e., 50% of the corresponding unfractionated heparin dose, is adequate to prevent clot formation in the extracorporeal system. Sixteen dialysis treatments of 4-5 h were given to each of six chronic dialysis patients. In dialyses 1, 2, 15 and 16 unfractionated heparin (initial dose 35 IU/kg, continuous dose 20 IU/kg/h) was given, and in dialyses 3-14 low molecular weight heparin (initial dose 17.5 anti-Xa U/kg, continuous dose 10 anti-X U/kg/h). At these dose levels of low molecular weight heparin, clot formation occurred in the extracorporeal system in five of the six patients, despite the fact that the plasma anti-Xa level of 0.5 U/ml recommended by the manufacturer had been attained. For this reason the continuous dose of low molecular weight heparin had to be raised to approx. 80% of the corresponding continuous dose of unfractionated heparin. A plasma anti-Xa level of 0.7 U/ml is necessary to prevent extracorporeal clot formation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835544     DOI: 10.1007/BF01748164

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  7 in total

1.  Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration.

Authors:  L O Andersson; T W Barrowcliffe; E Holmer; E A Johnson; G E Sims
Journal:  Thromb Res       Date:  1976-12       Impact factor: 3.944

2.  On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure.

Authors:  D A Lane; A Flynn; H Ireland; E Anastassiades; J R Curtis
Journal:  Haemostasis       Date:  1986

3.  Plasma heparin: a unique, practical, submicrogram-sensitive assay.

Authors:  E T Yin; S Wessler; J V Butler
Journal:  J Lab Clin Med       Date:  1973-02

4.  Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits.

Authors:  E Holmer; C Mattsson; S Nilsson
Journal:  Thromb Res       Date:  1982-03-15       Impact factor: 3.944

5.  Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin.

Authors:  C J Carter; J G Kelton; J Hirsh; M Gent
Journal:  Thromb Res       Date:  1981 Jan 1-15       Impact factor: 3.944

6.  A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.

Authors:  G Bratt; E Törnebohm; D Lockner; K Bergström
Journal:  Thromb Haemost       Date:  1985-04-22       Impact factor: 5.249

7.  Low molecular weight heparin in hemodialysis and hemofiltration patients.

Authors:  J Schrader; R Valentin; H J Tönnis; U Hildebrand; W Stibbe; V W Armstrong; M Kandt; H Köstering; E Quellhorst
Journal:  Kidney Int       Date:  1985-11       Impact factor: 10.612

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.